Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

Inclusion Criteria: * Agreed that female subjects or female partners of male subjects will not be pregnant during the study. * Chronic hepatitis B patients who are taking Entecavir at the Screening Visit for 6 months or longer * Have not used IFN alpha or antiviral drugs within the previous 6 months for treating hepatitis. * Have blood HBV DNA level of ≤300 copies/mL determined at Screening Visit * Have an ALT level less than or equal to 2 times the upper limit of normal \[ULN\] at the Screening Visit * Provide a signed voluntary written informed consent for study participation Exclusion Criteria: * Who have participated in other studies within previous 30 days from Screening Visit * Have the following decompensated liver parameters, * serum albumin level \<3 g/dL, * total bilirubin level \>2.5 mg/dL, * international normalized ratio (INR) \>1.8 * Do not have adequate renal function as determined by serum creatinine level 1.5 times more than normal range(1.2 mg/dL) * Had a previous liver transplant or bone marrow transplant * Are currently taking immunosuppressive or possible immunomodulatory drugs * Women who are pregnant or breastfeeding * female subjects will be pregnant or breastfeed during the study * History of allergy/hypersensitivity to drugs * Any clinically significant acute or chronic unstable renal, cardiac or endocrine disease (e.g., cardiac failure, renal failure, pancreatitis, diabetes mellitus) * Presence of any other primary or secondary hepatic disease (e.g., hemochromatosis, Wilson's disease, alcoholic hepatic disease, non alcoholic fatty liver, alpha-1-antitrypsin deficiency and so on) other than hepatitis B * Who were observed for hepatocellular mass by ultrasonography and have an abnormal increase of serum AFP * Past or present history of hepatocarcinoma * History of grand mal epilepsy, or currently on anti-epileptic medications * Occurrence of at least one episode of syncope within the last 12 months * Presence of an implantable cardiac device (pacemaker, automated implantable cardioverter defibrillator \[AICD\]) or implantable nerve stimulator * Who have arrhythmia * Any other conditions that are considered inappropriate for the study by the Investigator.